8-K: Aura Biosciences Updates Phase 3, Reports Q3 2025 Financials

Aura Biosciences provides updated timelines for its Phase 3 CoMpass trial in early choroidal melanoma, reports Q3 2025 financial results, and highlights positive immune profiling data for bel-sar in bladder cancer.

Summary

• Aura Biosciences announced its financial results for the third quarter ended September 30, 2025, and updated its corporate presentation.
• Enrollment for the global Phase 3 CoMpass trial in early choroidal melanoma is now expected to be completed in 2026.
• Topline data readout for the 15-month primary endpoint of the CoMpass trial is anticipated in the fourth quarter of 2027.
• Enrollment in the CoMpass trial has been slower than expected due to operational challenges and the requirement to document active tumor growth prior to patient enrollment.
• Measures implemented in 2025 have led to improved enrollment rates in recent months, with over 400 patients identified since June 2024 and 280 potentially eligible patients currently being followed.
• The Phase 1b/2 trial for bel-sar in non-muscle invasive bladder cancer (NMIBC) remains on track, with initial three-month clinical data expected in mid-2026.
• Phase 1 immune profiling data for bel-sar in NMIBC demonstrated robust induction of adaptive immune memory, including the generation of de novo mature tertiary lymphoid structures (TLS) in 3 out of 5 participants, and conversion of immune-cold to immune-hot microenvironments.
• The company has dosed the first patient in an ongoing Phase 2 clinical trial for metastases to the choroid and expanded entry criteria to include all solid tumors, with early proof of concept data expected in 2026.
• A Phase 1 proof-of-concept trial for cancers of the ocular surface is planned, with early data from Australian clinical sites expected in 2026.
• As of September 30, 2025, cash and cash equivalents and marketable securities totaled $161.9 million, providing an expected cash runway into the first half of 2027.
• Research and development expenses increased to $22.2 million for Q3 2025, up from $17.0 million for Q3 2024, primarily due to clinical trial progression and personnel growth.
• General and administrative expenses decreased to $5.7 million for Q3 2025, down from $6.2 million for Q3 2024, mainly due to reduced professional fees.
• Net loss for the three months ended September 30, 2025, was $26.1 million, compared to $21.0 million for the same period in 2024.

Sentiment

Score: 5

Explanation: Mixed sentiment. Positive clinical data and strong cash runway are offset by a significant delay in the Phase 3 trial's topline data and increased net loss. The delay in the most advanced trial is a notable concern for investors, despite the positive scientific findings and pipeline expansion.

Positives

• Bel-sar's immune profiling data reveal its potential to convert immune-cold to immune-hot tumors, supporting its use as a differentiated frontline therapy across the bladder cancer spectrum.
• The Phase 1b/2 NMIBC trial is actively enrolling and remains on track for initial three-month clinical data in mid-2026.
• The company expanded the entry criteria for its Phase 2 trial in metastases to the choroid to include all solid tumors, broadening the proof of concept.
• Cash and cash equivalents and marketable securities totaled $161.9 million as of September 30, 2025, providing an expected cash runway into the first half of 2027.
• General and administrative expenses decreased to $5.7 million in Q3 2025 from $6.2 million in Q3 2024, driven by reduced professional fees.
• Strong clinical demand and high investigator interest in the Phase 3 CoMpass trial, with over 400 patients pre-identified since June 2024 and 280 currently being followed.
• Bel-sar has received Orphan Drug Designation from the FDA and EMA, and Fast Track designation from the FDA for early choroidal melanoma and metastases to the choroid.
• The CoMpass trial is under a Special Protocol Assessment (SPA) agreement with the FDA, indicating regulatory concurrence on trial design.
• Bel-sar has the potential to become the first frontline vision-preserving therapy for early choroidal melanoma, an indication with no approved vision-preserving treatments.
• A single dose of bel-sar produced clinical complete responses in intermediateand high-risk NMIBC patients in the Phase 1 trial.
• A favorable safety profile was observed in the Phase 1 NMIBC trial, with no Grade 2/3 treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), or dose-limiting toxicities (DLTs) reported.

Negatives

• Enrollment in the Phase 3 CoMpass trial for early choroidal melanoma has been slower than expected due to operational challenges and the requirement to document active tumor growth.
• The topline data readout for the 15-month primary endpoint of the CoMpass trial is now expected in Q4 2027, indicating a delay in the timeline.
• Net loss for the three months ended September 30, 2025, increased to $26.1 million, compared to $21.0 million for the same period in 2024.
• Research and development expenses increased to $22.2 million for the three months ended September 30, 2025, from $17.0 million for the same period in 2024, contributing to the higher net loss.

Risks

• Uncertainties inherent in clinical trials and in the availability and timing of data from ongoing clinical trials.
• The expected timing for submissions for regulatory approval or review by governmental authorities may change.
• The risk that the results of preclinical and clinical trials may not be predictive of future results in connection with future clinical trials.
• The risk that early or interim data from ongoing clinical trials may not be predictive of final data from completed clinical trials.
• Governmental authorities may disagree with clinical trial designs, even where agreement has been obtained (e.g., Phase 3 Special Protocol agreement with the FDA).
• Uncertainty regarding whether regulatory approvals will be received to conduct trials or to market products.
• Whether the company's cash resources will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements.
• The company's ability to initiate, enroll, conduct or complete ongoing and planned clinical trials.
• Other risks and uncertainties described under the heading 'Risk Factors' in the company's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q.

Future Outlook

Aura Biosciences expects to complete enrollment for its Phase 3 CoMpass trial in early choroidal melanoma in 2026, with topline data for the 15-month primary endpoint anticipated in Q4 2027. Initial three-month clinical data from the Phase 1b/2 NMIBC trial are expected in mid-2026. Early proof of concept data from the Phase 2 trial in metastases to the choroid and the Phase 1 trial in cancers of the ocular surface are both expected in 2026. The company projects its current cash resources will fund operations into the first half of 2027.

Management Comments

• "In the third quarter, we remained focused on clinical execution in both our global Phase 3 CoMpass trial in early choroidal melanoma and our Phase 1b/2 trial in NMIBC."
• "Enrollment has taken longer than we expected in early choroidal melanoma due to the requirement to document active tumor growth prior to patient enrollment and other unique enrollment challenges with the first Phase 3 trial in this rare indication."
• "In 2025, we implemented measures to address these operational challenges and have experienced improved enrollment in recent months."
• "We believe we are now in a position to provide guidance regarding the topline data readout for the study."
• "Our NMIBC trial remains on track, with data expected in mid-2026."
• "Recently presented Phase 1 trial immune profiling data reinforce bel-sar's distinct dual mechanism, driving focal anti-tumor immune activation."
• "We believe these findings highlight bel-sar's potential as a differentiated frontline, organ-preserving treatment to deliver durable responses across the bladder cancer spectrum and in other solid tumors."

Industry Context

Aura Biosciences operates in the highly specialized and underserved fields of ocular and urologic oncology, focusing on precision therapies designed to preserve organ function. The company's lead candidate, bel-sar, targets early choroidal melanoma, an indication with no approved vision-preserving therapies, where the standard of care (radiotherapy) often leads to irreversible vision loss. In non-muscle invasive bladder cancer (NMIBC), bel-sar aims to address the high recurrence rates and significant treatment burden associated with conventional adjuvant therapies like BCG. The company's strategy to develop a first-in-class, organ-preserving therapy with a dual mechanism of action (direct tumor cell killing and immune activation) positions it to potentially disrupt existing treatment paradigms and capture significant market share in these areas of high unmet medical need, especially given the lack of direct competition in clinical development for its target patient populations.

Comparison to Industry Standards

• Bel-sar has the potential to become the first frontline vision-preserving therapy for early choroidal melanoma, contrasting with the current standard of care, radiotherapy, which frequently results in irreversible vision loss and high morbidity.
• In NMIBC, bel-sar's potential to induce adaptive immune memory and convert 'cold' to 'hot' tumors offers a differentiated approach compared to conventional adjuvant treatments like BCG, which often have suboptimal efficacy, high recurrence rates (e.g., ~75% after treatment), and significant side effects leading to discontinuation (e.g., 84% do not complete a full course of BCG).
• The company highlights that current bladder cancer therapies are invasive and lack durable efficacy, with patients often facing multiple recurrences and cumulative treatment burden, positioning bel-sar as a potential transformative frontline therapy designed for lasting benefit ahead of TURBT.
• Bel-sar's anticipated in-office administration for bladder cancer is designed to simplify delivery and support broader patient access, complementing existing standards, unlike more invasive or complex current treatments.
• The company notes that there are no approved therapies for metastases to the choroid or cancers of the ocular surface, indicating bel-sar's potential to fill significant therapeutic gaps in these high unmet medical need indications.

Stakeholder Impact

• Shareholders: Potential for increased value if clinical trials are successful, but delays in key trials and increased losses could lead to short-term price volatility. The extended cash runway provides stability.
• Patients (Early Choroidal Melanoma): Continued hope for a vision-preserving therapy, but the delay in Phase 3 data means a longer wait for potential approval.
• Patients (NMIBC, Metastases to Choroid, Ocular Surface Cancers): Positive early data and pipeline expansion offer new treatment prospects for high unmet medical needs.
• Employees: Continued focus on clinical execution and R&D, with growth in personnel expenses noted.
• Regulatory Authorities: Ongoing engagement with FDA, including SPA agreement for CoMpass trial and Fast Track designations.

Next Steps

• Complete enrollment for the Phase 3 CoMpass trial in early choroidal melanoma in 2026.
• Provide topline data readout for the 15-month primary endpoint of the CoMpass trial in Q4 2027.
• Release initial three-month clinical data from the Phase 1b/2 NMIBC trial in mid-2026.
• Release early proof of concept data from the Phase 2 trial in metastases to the choroid in 2026.
• Initiate a Phase 1 proof-of-concept trial for cancers of the ocular surface and release early data in 2026.
• Evaluate further expansion of inclusion criteria for the Phase 2 trial in metastases to the choroid.

Key Dates

Recommendation

While Aura Biosciences presents compelling positive Phase 1 data for bel-sar in bladder cancer and maintains a solid cash runway into 1H 2027, the significant delay in the topline data readout for the pivotal Phase 3 CoMpass trial in early choroidal melanoma to Q4 2027 is a material negative. This delay, coupled with an increased net loss, introduces uncertainty and extends the timeline to potential market entry for the lead candidate. The expansion of other pipeline programs and positive early data are encouraging, but the primary value driver's timeline extension warrants a cautious 'hold' stance. Investors should monitor enrollment progress and upcoming data readouts for NMIBC and other ocular indications, but the extended wait for the most advanced program's results suggests a period of consolidation rather than immediate upside.

Keywords

Aura Biosciences, AURA, biotechnology, clinical-stage, solid tumors, precision therapies, bel-sar, AU-011, choroidal melanoma, NMIBC, non-muscle invasive bladder cancer, ocular oncology, urologic oncology, Phase 3 CoMpass trial, Phase 1b/2 trial, financial results, Q3 2025, cash runway, immune profiling, VDC, virus-like drug conjugate, metastases to the choroid, cancers of the ocular surface, FDA Fast Track, Orphan Drug Designation, Special Protocol Assessment